News · PR

  • HOME
  • News · PR
  • Wes Wheeler joins Bushu Pharmaceuticals Holdings Limited as a Non-Executive Director

News · PR

Wes Wheeler joins Bushu Pharmaceuticals Holdings Limited as a Non-Executive Director

  • News

Saitama,Japan,April 25th,2017 – BushuPharmaceuticalsLimited(“Bushu”)announcesthatMr.Wes Wheeler will join the Board as a non-executive director of Bushu Pharmaceuticals Holdings Limited(“Bushu Holdings”). And he will be formally appointed in Shareholders’ meeting of Bushu Holdings which will be held in June 20th 2017.

Mr. Wheeler is currently the CEO and Chairman of Marken a leading global pharmaceutical supply chain and logistics company. Prior to Marken, Mr. Wheeler was the CEO and President of Patheon Inc., a leading global CMO. Baring Private Equity Asia (“Baring”) has been the shareholder of Bushu since acquiring 100% of the company in December 2014. Supporting further growth and globalization expansion has been a strategic priority for Bushu and Barings.

Commenting on the appointment, Jun Yokohama, CEO of Bushu, said “We look forward to having Mr. Wheeler join the Board and provide strategic advice on various initiatives including the further globalization of Bushu. His experience in leading top global pharmaceutical services companies and his top global industry contacts will be valuable to Bushu as the company continues to transform its business into a broader global platform. With the recently announced addition of Takeda Pharmaceutical Company Limited’s (“Takeda”) CMC business and ongoing partnership with Takeda, Mr. Wheeler can provide input on our strategy of leveraging off of Takeda’s development strengths.

Commenting on his appointment, Wes Wheeler said, “I am excited to be part of the Bushu team and support its further growth initiatives. Bushu has a strong reputation as the leading player in the Japan pharmaceutical CMO sector and continues to provide the highest quality service to its Japanese and multinational pharma customers. I look forward to working with Mr. Yokohama, the management team, and the shareholders Baring as they further transform Bushu with the recent addition of Takeda’s CMC business and continued growth both in Japan and overseas.

About Bushu

About Baring Private Equity Asia

News + PR



As a company specializing in contract manufacturing of pharmaceutical drugs, we offer a wide range of contract services tailored to clients’ needs based on our extensive experience and know-how accumulated over many years.